- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00004029
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A PHASE I TRIAL OF RECOMBINANT VACCINIA VIRUS THAT EXPRESSES PSA IN PATIENTS WITH ADENOCARCINOMA OF THE PROSTATE
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
I. Assess the toxicity associated with repeated vaccination with recombinant vaccinia virus expressing prostate-specific antigen (rV-PSA) in patients with metastatic adenocarcinoma of the prostate.
II. Determine the optimal dose of rV-PSA given at monthly intervals based on cellular and hormonal immunity.
III. Determine whether vaccination with rV-PSA is associated with anti-tumor activity.
IV. Determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) has an effect on cellular and humoral immunity different from rV-PSA, and whether the addition of GM-CSF has enhanced antitumor effect compared to rV-PSA alone.
OUTLINE: This is an open label, dose escalation study.
Patients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
Patients are followed monthly for 6 months.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stati Uniti, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma of the prostate with evidence of metastatic disease based on any of the following:
- Lymph node positive and PSA at least 10 ng/mL
- Bone scan positive and PSA at least 10 ng/mL
- PSA at least 2 ng/mL and rising following radical prostatectomy
- PSA at least 10 ng/mL following radiotherapy
- No symptomatic metastatic disease (bony pain)
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: ECOG 0 or 1
- WBC greater than 2,000/mm3
- Platelet count greater than 100,000/mm3
- Bilirubin less than 2.0 mg/dL
- AST less than 4 times normal
- Creatinine less than 2.0 mg/dL
- Must be type HLA-A2 Prior vaccinia (smallpox) exposure required
- At least normal delayed type hypersensitivity to mumps and Candida
- At least normal CD4:CD8 ratio (greater than 1)
- At least normal lymphocyte proliferation testing (to Con A)
- At least normal immunoglobulin levels
- No evidence of altered immune responsiveness or autoimmune syndromes (e.g., scleroderma, systemic lupus erythematosus)
- No HIV antibody No prior splenectomy
- No known allergy to eggs
- No active extensive skin disorders (e.g, psoriasis, burns, impetigo, disseminated zoster)
- No other serious intercurrent illness
- No active infections unless cleared and at least 3 days since antibiotic therapy
No close contact for 2 weeks after each vaccination with the following people:
- Children less than 3 years old
- Pregnant women
- Individuals with eczema or skin conditions listed above
- Immunosuppressed individuals
PRIOR CONCURRENT THERAPY:
- No concurrent biologic therapy
- No prior chemotherapy for metastatic disease
- No prior hormone therapy for metastatic disease
- Neoadjuvant hormone therapy prior to prostatectomy or radiotherapy allowed
- No concurrent steroids or hormonal medications
- Prior radiotherapy allowed
- Prior surgery allowed
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Arm I
atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity.
Response assessment is performed at eight weeks.
Patients who discontinue therapy prior to eight weeks are considered unevaluable for response.
If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level.
Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle.
Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant prostate specific antigen expressing vaccinia virus vaccine, PROSTVAC (rV-PSA) in advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 18: A1692, 439, 1999.
- Eder JP Jr, Kantoff PW, Bubley GJ, et al.: A phase I trial of recombinant vaccinia virus, PROSTVAC that expresses prostate specific antigen (rV-PSA) as a vaccine in men with advanced prostate cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 17: A1672, 434, 1998.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CDR0000065275
- DFCI-96079
- NCI-T95-0086H
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro alla prostata
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su sargramostim
-
Milton S. Hershey Medical CenterRitiratoPolmonite | Sindrome da distress respiratorio acuto | Infezione da virus respiratorio
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletatoCancro alla prostataStati Uniti
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletatoCancro metastatico | Melanoma (pelle)Stati Uniti
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletatoCancro ai reni | Cancro metastaticoStati Uniti, Canada
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)Sconosciuto
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completato
-
Roswell Park Cancer InstituteCompletatoLinfoma | Sindromi mielodisplastiche | Leucemia | Malattie mieloproliferative croniche | Malattia del trapianto contro l'ospite | Neoplasie mielodisplastiche/mieloproliferativeStati Uniti
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletatoCancro metastatico | Melanoma (pelle)Stati Uniti
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletatoSindromi mielodisplastiche | Leucemia | Malattie mielodisplastiche/mieloproliferativeStati Uniti
-
SanofiRitirato